Zykadia (R) (Ceritinib) in the First Line leads to advanced, ALK-positive NSCLC to a PFS of 16.6 or 26.3 Months, if no Brain Metastases were present at the Time of Diagnosis-MedSci.cn

Zykadia (R) (Ceritinib) in the First Line leads to advanced, ALK-positive NSCLC to a PFS of 16.6 or 26.3 Months, if no Brain Metastases were present at the Time of Diagnosis

Dinkhoff, K

Dinkhoff, K (reprint author), Novartis Pharma GmbH, Nurnberg, Germany.

ONCOLOGY RESEARCH AND TREATMENT, 2017; 40 (3): 160

科室
- - 订阅+
  - 更多科室
工具
服务